Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00216775

Enrollment

Registered

2005-09-22

Start date

2004-12-31

Completion date

2008-05-31

Last updated

2015-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Chronic

Brief summary

The purpose of this study is to evaluate the efficacy and safety of low-dose interferon-alfa-2b plus ribavirin compared to the standard-dose of the same combination in patients with chronic hepatitis C.

Interventions

DRUGinterferon-alfa-2b and ribavirin

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Chronic Hepatitis C. Must be infected with genotype 1b viruses

Exclusion criteria

* Hemoglobin levels\<8.5g/dL, * Platelet counts\<50,000/mm3, * Total polymorphonuclear counts\<1000/mm3 * Pregnancy, * Renal dysfunction,

Design outcomes

Primary

Measure	Time frame
rate of sustained viral response	6 months

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026